State-Specific Pricing Disclosures
Bristol Myers Squibb (BMS) is committed to price transparency. The information in the state-specific disclosures below provides the list price of BMS medications, as required by these states. Please note that the price of BMS medications does not vary by state, and most patients will pay less than the list price
State-specific pricing disclosures may be viewed below.
Pursuant to Colorado Rev. Stat. § 12-280-308, BMS is required, when engaging in prescription drug marketing, to provide the wholesale acquisition cost (WAC) of our drugs to Colorado prescribers. Prices paid by consumers may vary from the list price. Please click on the links below for product-specific disclosure information.
ABECMA®
(idecabtagene vicleucel)
ABRAXANE®
(paclitaxel protein-bound)
AUGTYRO™
(repotrectinib)
AZACTAM®
(aztreonam for injection)
BARACLUDE®
(entecavir)
BREYANZI®
(lisocabtagene maraleucel)
CAMZYOS®
(mavacamten)
COBENFY™
(xanomeline and trospium chloride)
ELIQUIS®
(apixaban)
EMPLICITI®
(elotuzumab)
EVOTAZ®
(atazanavir and cobicistat)
IDHIFA®
(enasidenib mesylate)
INREBIC®
(fedratinib)
ISTODAX®
(romidepsin)
KENALOG®
(triamcinolone acetonide injectable suspension, USP)
KRAZATI®
(adagrasib)
NULOJIX®
(belatacept)
ONUREG®
(azacitidine)
OPDIVO®
(nivolumab)
OPDIVO QVANTIG™
(nivolumab + hyaluronidase-nvhy)
OPDUALAG™
(nivolumab and relatlimab-rmbw)
ORENCIA®-INJECT
(abatacept)
ORENCIA®-IV
(abatacept)
POMALYST®
(pomalidomide)
REBLOZYL®
(luspatercept-aamt)
REVLIMID®
(lenalidomide)
REYATAZ®
(atazanavir)
SOTYKTU®
(deucravacitinib)
SPRYCEL®
(dasatinib)
THALOMID®
(thalidomide)
VIDAZA®
(azacitidine)
YERVOY®
(ipilimumab)
ZEPOSIA®
(ozanimod)
Pursuant to Connecticut Public Act No. 23-171, BMS is required, when engaging in prescription drug marketing, to provide pricing information regarding BMS products to prescribing practitioners or pharmacists. Prices paid by consumers may vary from the list price. Please click on the links below for product-specific disclosure information.
ABECMA®
(idecabtagene vicleucel)
ABRAXANE®
(paclitaxel protein-bound)
AUGTYRO™
(repotrectinib)
AZACTAM®
(aztreonam for injection)
BARACLUDE®
(entecavir)
BREYANZI®
(lisocabtagene maraleucel)
CAMZYOS®
(mavacamten)
COBENFY™
(xanomeline and trospium chloride)
ELIQUIS®
(apixaban)
EMPLICITI®
(elotuzumab)
EVOTAZ®
(atazanavir and cobicistat)
IDHIFA®
(enasidenib mesylate)
INREBIC®
(fedratinib)
ISTODAX®
(romidepsin)
KENALOG®
(triamcinolone acetonide injectable suspension, USP)
KRAZATI®
(adagrasib)
NULOJIX®
(belatacept)
ONUREG®
(azacitidine)
OPDIVO®
(nivolumab)
OPDIVO QVANTIG™
(nivolumab + hyaluronidase-nvhy)
OPDUALAG™
(nivolumab and relatlimab-rmbw)
ORENCIA®-INJECT
(abatacept)
ORENCIA®-IV
(abatacept)
POMALYST®
(pomalidomide)
REBLOZYL®
(luspatercept-aamt)
REVLIMID®
(lenalidomide)
REYATAZ®
(atazanavir)
SOTYKTU®
(deucravacitinib)
SPRYCEL®
(dasatinib)
THALOMID®
(thalidomide)
VIDAZA®
(azacitidine)
YERVOY®
(ipilimumab)
ZEPOSIA®
(ozanimod)
Pursuant to Vermont’s Pharmaceutical Marketer Price Disclosure Law, 18 V.S.A. § 4633, BMS is required, when engaging in prescription drug marketing, to disclose to Vermont physicians and other prescribers the average wholesale price (AWP) of drugs we market within the state. Prices paid by consumers may vary from the list price. Please click on the links below for product-specific disclosure information.
AUGTYRO™
(repotrectinib)
CAMZYOS®
(mavacamten)
COBENFY™
(xanomeline and trospium chloride)
ELIQUIS®
(apixaban)
IDHIFA®
(enasidenib mesylate)
INREBIC®
(fedratinib)
KRAZATI®
(adagrasib)
ONUREG®
(azacitidine)
POMALYST®
(pomalidomide)
REVLIMID®
(lenalidomide)
SOTYKTU®
(deucravacitinib)
SPRYCEL®
(dasatinib)
ZEPOSIA®
(ozanimod)
Bristol Myers Squibb is committed to helping patients with access to our medicines. To learn more about access and affordability options, visit www.BMSPatientSupportResources.com and select the appropriate medication for more information.